Literature DB >> 28513113

Retina and Nerve Fiber Layer Thickness in Eyes with Thyroid-Associated Ophthalmopathy.

Sharon Blum Meirovitch1, Igal Leibovitch1, Anat Kesler1, David Varssano1, Amir Rosenblatt1, Meira Neudorfer1.   

Abstract

BACKGROUND: Thyroid-associated ophthalmopathy (TAO) is an inflammatory disease that affects the thyroid gland and the eye orbit. Of patients with TAO, 3%-5% have severe sight-threatening disease due to optic neuropathy Optical coherence tomography (OCT), the non-invasive imaging technology that yields high-resolution cross-sectional images of the retina, provides qualitative and quantitative data on the retina.
OBJECTIVES: To apply this technique to quantitatively assess retinal nerve fiber layer (RNFL) and macular ring thicknesses in healthy subjects and in patients with TAO to determine their relationship to the severity of the orbital disease.
METHODS: All patients in the ophthalmology clinic who were diagnosed with TAO and underwent OCT imaging as part of their ocular examination comprised the study group, and healthy patients who volunteered to undergo OCT examination served as controls. Results of the complete ophthalmologic examination and OCT findings were collected from medical files, including the thickness of the RNFL and the macula.
RESULTS: The study comprised 21 patients and 41 healthy controls. TAO patients exhibited RNFL thickening and inner macula thinning compared to healthy subjects. Mean RNFL thickness was correlated with the severity of the orbital disease.
CONCLUSIONS: The OCT findings suggest that the retina is involved in TAO, probably as early as the subclinical stage. This highlights the ability of OCT to identify retinal changes earlier and far more accurately than is detected today, enabling earlier diagnosis and more timely treatment to prevent severe visual sequelae.

Entities:  

Mesh:

Year:  2017        PMID: 28513113

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  7 in total

1.  Retinal and circumpapillary nerve fiber layer thickness and associated factors in children.

Authors:  Yao Yao; Jing Fu; Lei Li; Weiwei Chen; Zhaojun Meng; Han Su; Wei Dai
Journal:  Eye (Lond)       Date:  2020-11-25       Impact factor: 4.456

2.  Thicknesses of the retinal layers in patients with Graves' disease with or without orbitopathy.

Authors:  Berna Evranos Ogmen; Nagihan Ugurlu; Muhammet Cuneyt Bilginer; Sefika Burcak Polat; Birgul Genc; Reyhan Ersoy; Bekir Cakir
Journal:  Int Ophthalmol       Date:  2022-05-12       Impact factor: 2.029

3.  The changes of retinal nerve fibre layer and ganglion cell layer with different severity of thyroid eye disease.

Authors:  Jie Guo; Xiaofeng Li; Ruiqi Ma; Lu Gan; Jiang Qian
Journal:  Eye (Lond)       Date:  2021-02-26       Impact factor: 3.775

4.  Functional and Morphological Changes in the Visual Pathway in Patients with Graves' Orbitopathy.

Authors:  Agnieszka Jagiełło-Korzeniowska; Agata Bałdys-Waligórska; Alicja Hubalewska-Dydejczyk; Bożena Romanowska-Dixon
Journal:  J Clin Med       Date:  2022-07-15       Impact factor: 4.964

5.  Alterations in Spontaneous Neuronal Activity and Microvascular Density of the Optic Nerve Head in Active Thyroid-Associated Ophthalmopathy.

Authors:  Pingyi Zhu; Zihui Liu; Yi Lu; Yu Wang; Danbin Zhang; Pinghui Zhao; Lulu Lin; Nimo Mohamed Hussein; Xiaozheng Liu; Zhihan Yan; Guanghui Bai; Yunhai Tu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

6.  Peripapillary structural and microvascular alterations in early dysthyroid optic neuropathy.

Authors:  Yufei Wu; Qiaoli Yang; Liujun Ding; Yunhai Tu; Xiaoyu Deng; Yan Yang; Meixiao Shen; Qinkang Lu; Fan Lu; Qi Chen
Journal:  Eye Vis (Lond)       Date:  2022-08-09

7.  Reduced macular inner retinal thickness and microvascular density in the early stage of patients with dysthyroid optic neuropathy.

Authors:  Yufei Wu; Yunhai Tu; Chaoming Wu; Lulu Bao; Jianhua Wang; Fan Lu; Meixiao Shen; Qi Chen
Journal:  Eye Vis (Lond)       Date:  2020-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.